Abiomed Sales Boosted By Impella Reorders In Fiscal Q4
This article was originally published in The Gray Sheet
Executive Summary
Abiomed sales advanced 17% to $23 million for the most recent fiscal quarter, driven by Impella percutaneous cardiac assist system reorders, despite 68% slower growth in the customer base
You may also be interested in...
Abiomed Impella 5.0
Firm gains 510(k) clearance for its Impella 5.0 and Impella LD minimally invasive catheter-based circulatory support pumps, which provide circulatory support for up to six hours. The pumps are driven by the same console as the Impella 2.5, which was cleared by FDA in June 2008, but provide up to five liters of blood flow per minute instead of 2.5 1("The Gray Sheet" June 9, 2008, p. 20). While the 5.0 version is implanted via the femoral artery (as is the 2.5 model), the LD model is inserted through the chest. The devices can provide a therapeutic benefit from "ventricular unloading," the company explains (2"The Gray Sheet" Nov. 17, 2008, p. 5)
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.